会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明授权
    • Viral production process
    • 病毒生产过程
    • US5994134A
    • 1999-11-30
    • US73076
    • 1998-05-04
    • Daniel D. GirouxAnn M. GoudreauMuralidhara RamachandraPaul W. Shabram
    • Daniel D. GirouxAnn M. GoudreauMuralidhara RamachandraPaul W. Shabram
    • C12N15/09C12N5/10C12N7/00C12N7/01
    • C12N7/00A61K48/0091C12N15/86C12N2531/00C12N2710/10043C12N2710/10343Y10S435/948
    • The present invention is directed to a method of producing recombinant viral vectors at high titers incorporating a variety of important advancements over the art. The method of the present invention incorporates multiple features which provide enhanced production of viruses, particularly those viruses encoding exogenous transgenes. The specifically illustrated method describes a method for the high titer serum-free media production of recombinant replication defective adenoviruses containing an exogenous transgene. The invention provides methods of preparing microcarriers, methods for seeding bioreactors at high cell density, increasing the infectivity of the producer cells to the virus, methods to increase product yield through synchronization of the cell cycle of the producer cells, and methods to minimize the deleterious effects of exogenous transgenes. The invention further provides producer cells prepared by the process of the invention. The invention further provides viruses produced by the process.
    • 本发明涉及以高滴度生产重组病毒载体的方法,其结合了本领域的各种重要进展。 本发明的方法结合了多个特征,其提供增强的病毒生产,特别是编码外源转基因的那些病毒。 具体说明的方法描述了含有外源转基因的重组复制缺陷型腺病毒的高滴度无血清培养基的制备方法。 本发明提供了制备微载体的方法,用于以高细胞密度接种生物反应器的方法,增加生产细胞对病毒的感染性,通过生产细胞的细胞周期同步来提高产量的方法,以及使有害细菌最小化的方法 外源转基因的作用。 本发明还提供了通过本发明的方法制备的生产细胞。 本发明还提供了通过该方法产生的病毒。
    • 3. 发明授权
    • Selectivity replicating viral vector
    • 选择性复制病毒载体
    • US07691370B2
    • 2010-04-06
    • US10062216
    • 2002-01-30
    • Muralidhara RamachandraPaul W. Shabram
    • Muralidhara RamachandraPaul W. Shabram
    • A01N63/00A61K35/713A61K48/00C07H21/04C12N15/00C12N15/12C12N15/34
    • C12N15/86A61K48/00C12N2710/10332C12N2710/10343C12N2830/00C12N2830/001C12N2830/15
    • The present invention provides recombinant viruses which replicate the viral genome selectively in response to the intracellular conditions of the target cell through the use a pathway-responsive promoter which substantially inhibits viral replication in the host cell based on the phenotypic or genotypic of the infected cell. In the target cell, the promoter element of the pathway-responsive promoter is inactive and thus the virus is permitted to replicate. This results in: (1) killing the cells by natural lytic nature of the virus, and/or (2) provides a therapeutic dose of a transgene product (amplified in comparison to replication incompetent vectors) to the target cell, and (3) producing a localized concentration of the virus facilitating the infection of surrounding cells to the recombinant virus. The invention further provides therapeutic and diagnostic methods of use of the vectors, pharmaceutical formulations comprising the vectors, methods of making the vectors and transformed cells comprising the vectors.
    • 本发明提供了通过使用基于感染细胞的表型或基因型基本上抑制宿主细胞中的病毒复制的途径反应性启动子来响应于靶细胞的细胞内条件而选择性复制病毒基因的重组病毒。 在靶细胞中,途径反应性启动子的启动子元件是无活性的,因此病毒被允许复制。 这导致:(1)通过病毒的天然裂解性质杀死细胞,和/或(2)向靶细胞提供治疗剂量的转基因产物(与复制无能载体相比扩增),和(3) 产生该病毒的局部浓度,促进周围细胞感染重组病毒。 本发明还提供了使用载体的治疗和诊断方法,包含载体的药物制剂,制备载体的方法和包含载体的转化细胞。
    • 5. 发明申请
    • NANOCOATINGS FOR BIOLOGICAL MATERIALS
    • 生物材料纳米技术
    • US20120308660A1
    • 2012-12-06
    • US13486949
    • 2012-06-01
    • Amish PATELPaul W. SHABRAM
    • Amish PATELPaul W. SHABRAM
    • A61K39/235A61P31/14A61K9/50
    • A61K39/00A61K2039/5258A61K2039/60C12N7/00C12N2710/10034
    • The present invention provides formulations comprising nanocoated biological materials (e.g., viral particles), methods for producing powders comprising nanocoated biological materials, and powders produced from such formulations and methods. Also provided are pharmaceutical compositions comprising the present formulations or dried powders, and vaccines comprising the present formulations or dried powders. The nanocoated biological materials typically display superior stability for either direct use in a formulation or in drying processes to produce a powder material, wherein the coated materials are typically more tolerant to environmental stress (e.g., chemical, thermal, and/or mechanical stress) during storage or drying processes.
    • 本发明提供了包含纳米化生物材料(例如病毒颗粒),用于制备包含纳米化生物材料的粉末的方法,以及由这些制剂和方法制备的粉末的制剂。 还提供了包含本发明制剂或干燥粉末的药物组合物,以及包含本发明制剂或干燥粉末的疫苗。 纳米填充的生物材料通常显示出优异的稳定性,用于在制剂中直接使用或在干燥过程中产生粉末材料,其中涂覆的材料通常在环境应力(例如,化学,热和/或机械应力)期间更耐受 储存或干燥过程。
    • 6. 发明授权
    • Selectively replicating viral vectors
    • 选择性复制病毒载体
    • US08133481B2
    • 2012-03-13
    • US12706134
    • 2010-02-16
    • Muralidhara RamachandraPaul W. Shabram
    • Muralidhara RamachandraPaul W. Shabram
    • A01N63/00A61K35/713A61K48/00C07H21/04C12N15/00C12N15/12C12N15/34
    • C12N15/86A61K48/00C12N2710/10332C12N2710/10343C12N2830/00C12N2830/001C12N2830/15
    • The present invention provides recombinant viruses which replicate the viral genome selectively in response to the intracellular conditions of the target cell through the use a pathway-responsive promoter which substantially inhibits viral replication in the host cell based on the phenotypic or genotypic of the infected cell. In the target cell, the promoter element of the pathway-responsive promoter is inactive and thus the virus is permitted to replicate. This results in: (1) killing the cells by natural lytic nature of the virus, and/or (2) provides a therapeutic dose of a transgene product (amplified in comparison to replication incompetent vectors) to the target cell, and (3) producing a localized concentration of the virus facilitating the infection of surrounding cells to the recombinant virus. The invention further provides therapeutic and diagnostic methods of use of the vectors, pharmaceutical formulations comprising the vectors, methods of making the vectors and transformed cells comprising the vectors.
    • 本发明提供了通过使用基于感染细胞的表型或基因型基本上抑制宿主细胞中的病毒复制的途径反应性启动子来响应于靶细胞的细胞内条件而选择性复制病毒基因的重组病毒。 在靶细胞中,途径反应性启动子的启动子元件是无活性的,因此病毒被允许复制。 这导致:(1)通过病毒的天然裂解性质杀死细胞,和/或(2)向靶细胞提供治疗剂量的转基因产物(与复制无能载体相比扩增),和(3) 产生该病毒的局部浓度,促进周围细胞感染重组病毒。 本发明还提供了使用载体的治疗和诊断方法,包含载体的药物制剂,制备载体的方法和包含载体的转化细胞。
    • 8. 发明申请
    • SELECTIVELY REPLICATING VIRAL VECTORS
    • 选择性地更改病毒载体
    • US20100266546A1
    • 2010-10-21
    • US12706134
    • 2010-02-16
    • Muralidhara RamachandraPaul W. Shabram
    • Muralidhara RamachandraPaul W. Shabram
    • A61K35/76C12N7/01C12N15/63C12N5/00C12N5/09C12Q1/70A61P35/00
    • C12N15/86A61K48/00C12N2710/10332C12N2710/10343C12N2830/00C12N2830/001C12N2830/15
    • The present invention provides recombinant viruses which replicate the viral genome selectively in response to the intracellular conditions of the target cell through the use a pathway-responsive promoter which substantially inhibits viral replication in the host cell based on the phenotypic or genotypic of the infected cell. In the target cell, the promoter element of the pathway-responsive promoter is inactive and thus the virus is permitted to replicate. This results in: (1) killing the cells by natural lytic nature of the virus, and/or (2) provides a therapeutic dose of a transgene product (amplified in comparison to replication incompetent vectors) to the target cell, and (3) producing a localized concentration of the virus facilitating the infection of surrounding cells to the recombinant virus. The invention further provides therapeutic and diagnostic methods of use of the vectors, pharmaceutical formulations comprising the vectors, methods of making the vectors and transformed cells comprising the vectors.
    • 本发明提供了通过使用基于感染细胞的表型或基因型基本上抑制宿主细胞中的病毒复制的途径反应性启动子来响应于靶细胞的细胞内条件而选择性复制病毒基因的重组病毒。 在靶细胞中,途径反应性启动子的启动子元件是无活性的,因此病毒被允许复制。 这导致:(1)通过病毒的天然裂解性质杀死细胞,和/或(2)向靶细胞提供治疗剂量的转基因产物(与复制无能载体相比扩增),和(3) 产生该病毒的局部浓度,促进周围细胞感染重组病毒。 本发明还提供了使用载体的治疗和诊断方法,包含载体的药物制剂,制备载体的方法和包含载体的转化细胞。
    • 9. 发明授权
    • Calpain inhibitors and their applications
    • 钙蛋白酶抑制剂及其应用
    • US07001770B1
    • 2006-02-21
    • US09416735
    • 1999-10-13
    • Isabella A. AtencioDrake M. LaFaceMuralidhara RamachandraPaul W. Shabram
    • Isabella A. AtencioDrake M. LaFaceMuralidhara RamachandraPaul W. Shabram
    • C12N15/00C12N15/63C12N15/85C12N15/86
    • C12N15/86A61K38/1709A61K38/1758A61K45/06C12N2710/10332C12N2710/10343
    • The present invention provides a method to enhance apoptosis in a cell by the administration of p53 in combination with a calpain inhibitor. The present invention provides a method of increasing the infectivity of a cell to a viral vector by treatment of the cell with a calpain inhibitor. the present invention further provides a method of enhancing transciption of a therapeutic transgene from the CMV promoter. The present invention also provides a method of suppress the in vivo CTL response to viral vectors by the use of calpain inhibitors. The present invention further provides a pharmaceutical formulations of p53 and a calpain inhibitor in a pharmaceutically acceptable carrier. The present invention provides a method of ablating neoplastic cells in a mammalian organism in vivo by the co-administration of a calpain inhibitor and p53. The present invention also provides a method of ablating neoplastic cells in a population of normal cells contaminated by said neoplastic cells ex vivo by the administration of a recombinant adenovirus in combination with a calpain inhibitor to said population.
    • 本发明提供了通过与钙蛋白酶抑制剂组合施用p53来增强细胞凋亡的方法。 本发明提供了通过用钙蛋白酶抑制剂处理细胞来增加细胞对病毒载体的感染性的方法。 本发明还提供了增强来自CMV启动子的治疗性转基因的转录的方法。 本发明还提供了通过使用钙蛋白酶抑制剂抑制对病毒载体的体内CTL应答的方法。 本发明进一步提供药学上可接受的载体中的p53和钙蛋白酶抑制剂的药物制剂。 本发明提供了通过共同给予钙蛋白酶抑制剂和p53来体内在哺乳动物生物体内消化肿瘤细胞的方法。 本发明还提供了一种通过将重组腺病毒与钙蛋白酶抑制剂组合给所述群体而在体外从所述赘生性细胞污染的正常细胞群体中消化肿瘤细胞的方法。